Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)

This study is a two-arm phase II randomized trial investigating patients with luminal subtype muscle-invasive bladder cancer (MIBC) receiving neoadjuvant therapy (NAT) followed by cystectomy compared to those receiving upfront cystectomy.

Trial Details

NCT ID

NCT07762586

Phase

PHASE2

Sponsor

Rutgers, The State University of New Jersey

Status

RECRUITING

Cancer Type

Bladder Cancer

Interventions

Neoadjuvant Therapy
Upfront radical cystectomy

Locations (sample)

New Brunswick, New Jersey, United States|40.48622,-74.45182

Key Eligibility Criteria

▪ Inclusion Criteria
Willing and able to provide informed consent
Age ≥18 years old
Eligible to receive standard of care systemic neoadjuvant therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →